Patent intelligence · US
US 12252511
Process for the preparation of cyclic depsipeptides
Process for the preparation of cyclic depsipeptides
Patent details — US 12252511
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 18, 2025
- Expiration
- Mar 13, 2045
- Applicant
- OnKure, Inc.
- Claims
- 6
- CPC classes
- A61K, A61K38/15, A61P, A61P25/00
Quick answer
US 12252511 (Process for the preparation of cyclic depsipeptides) is held by OnKure, Inc.. Status: granted. Granted Mar 18, 2025. Expires Mar 13, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- OnKure, Inc.
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61K, A61K38/15, A61P, A61P25/00, A61P29/00, A61P35/00
More from OnKure, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11739123
Process for the preparation of cyclic depsipeptides
granted -
US 11339150
Benzimidazole compounds as HDAC6 inhibitors
granted -
US 11203602
Thioester prodrugs of macrocycles as inhibitors of histone deacetylases
granted -
US 11053284
Process for the preparation of cyclic depsipeptides
granted -
US 10689419
Process for the preparation of cyclic depsipeptides
granted -
US 10100089
Process for the preparation of cyclic depsipeptides
granted
Frequently asked questions
What is US patent 12252511?
US 12252511 (Process for the preparation of cyclic depsipeptides) is held by OnKure, Inc.. Status: granted. Granted Mar 18, 2025. Expires Mar 13, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12252511?
OnKure, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 12252511 expire?
Our index shows an expiration date of Mar 13, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.